2004
DOI: 10.1016/j.ijantimicag.2003.07.013
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
5
0

Year Published

2005
2005
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 13 publications
1
5
0
Order By: Relevance
“…Figure 1 illustrates the similarity in response between dalbavancin treatment and linezolid treatment for clinical, microbiological, and overall response at both the EOT visit and the TOC visit, thus conferring clinical relevance to the statistical conclusion of noninferiority for the primary end point. The high rates of clinical success were comparable to published clinical cure rates for linezolid, oxacillin/dicloxacillin, and flucloxacillin and higher than published rates for daptomycin, ertapenem, piperacillintazobactam, and quinupristin/dalfopristin [10][11][12][13][14][15]. Durability of clinical success was supported by post-TOC visit patient reports of low rates of antibacterial use and lack of signs or symptoms of SSSI.…”
Section: Discussionsupporting
confidence: 68%
“…Figure 1 illustrates the similarity in response between dalbavancin treatment and linezolid treatment for clinical, microbiological, and overall response at both the EOT visit and the TOC visit, thus conferring clinical relevance to the statistical conclusion of noninferiority for the primary end point. The high rates of clinical success were comparable to published clinical cure rates for linezolid, oxacillin/dicloxacillin, and flucloxacillin and higher than published rates for daptomycin, ertapenem, piperacillintazobactam, and quinupristin/dalfopristin [10][11][12][13][14][15]. Durability of clinical success was supported by post-TOC visit patient reports of low rates of antibacterial use and lack of signs or symptoms of SSSI.…”
Section: Discussionsupporting
confidence: 68%
“…The use of such narrower spectrum carbapenem when the infection is not complicated and MRSA is not suspected may be proper step toward antibiotic stewardship and the prevention of resistance (Gesser, McCarroll, & Woods, 2004;Jacqueline et al, 2005Jacqueline et al, , 2006.…”
Section: Discussionmentioning
confidence: 99%
“…1 This period of stability at room temperature after refrigerated storage supports ertapenem's utility in hospital and outpatient settings, as mentioned in previous studies. 4,9,10,16 Given the relatively short stability at room temperature and at 4 °C, we sought to find a long-term storage solution by freezing the 100-mg/mL syringes. During these experiments, we observed that 20-mL syringes prepared with 10 mL of ertapenem solution completely thawed within 60 minutes after removal from the freezer.…”
Section: Discussionmentioning
confidence: 99%